Hepatitis A
Hepatitis A
Hepatitis A
MEDICAL
UNIVERSITY
Name: Zakarya kamal Sattouf
Group: 180B
Subject: Hepatitis A
Date: 11/13/2019
What Is Hepatitis A?
• Hepatitis A is a liver disease caused by the hepatitis A virus
(HAV). The virus is primarily spread when an uninfected
(and unvaccinated) person ingests food or water that is
contaminated with the faces of an infected person. The
disease is closely associated with unsafe water or food,
inadequate sanitation, poor personal hygiene and oral-anal
Definition
sex.
The coding region of the genome codes for 4 structural proteins and 7
Etiology
nonstructural proteins.
Lifecycle of HAV
1. Oral inoculation of fecally excreted virus.
2. Transportation across gastrointestinal epithelium to mesenteric veins of
liver (viremia).
3. Taken up by hepatocytes, replicates, and shed into the bile canal.
4. Transported to the intestine and excreted into the feces
EPIDEMIOLOGY
EPIDEMIOLOGY
Hepatitis A Transmission
People who are infected can start spreading the infection (shedding virus)
about 1 week after their own exposure. People who do not have symptoms
can still spread the virus. Infection with HAV occurs throughout the world.
Transmission
is likely to occur, such as daycare centers, prisons, and mental institutions.
People at increased risk for hepatitis A infection include:
Risk Factors.
4. Consumption of shellfish from contaminated water.
5. Daycare children and daycare workers.
6. Blood transfusion or blood products are very rarely associated with
HAV.
7. Injection and no injection drug use.
What Are the Symptoms of Hepatitis A?
symptoms
4. Nausea
5. Fever
6. Diarrhea
7. Fatigue
Children often have the disease with few symptoms.
You can spread the hepatitis A virus about 2 weeks before
your symptoms appear and during the first week they
show up, or even if you don't have.
Complications of Hepatitis A
Hepatitis A can cause more serious health problems. Keep in mind all
that these are rare and more likely to happen in people who are over 50.
Liver failure . This usually affects people who are:
Older
Already have another type of liver disease
Have a weakened immune system
Complications
Guillain-Barre syndrome. With this disorder, your immune system
attacks your nervous system. It causes muscle weakness and even
paralysis. You’ll need to be treated in a hospital to ease your symptoms
and make you heal faster. You’ll get high-dose immunoglobulin therapy.
This mix of proteins delivered through an IV will boost your immune
system.
Diagnose
elevated lifelong, and confers protective
abdominal US or CT scan may be
immunity against HAV.
helpful to
demonstrate hepatomegaly and
2. CBC (Complete blood count).
Routinely ordered on hospitalized
splenomegaly in association with
patients
HAV infection
but nonspecific.
(common in icteric phase of HAV)
but usually reserved to evaluate
cases with
concerns for cholelithiasis and
choledocholithiasis
Treatment.
Virus-specific therapy is not available for HAV; therefore,
treatment is mainly supportive measures, avoidance of hepatic
toxins (less than 2
g/day acetaminophen), and alcohol, vaccination, and prevention.
Indication for
evaluation for liver transplantation includes:
Treatment
1. Fulminant HAV.
2. Jaundice lasting more than 7 days before encephalopathy
(indicating
extensive liver necrosis). 3. Serum bilirubin greater than or equal to
17 mg/dL
Prevention.
Vaccination of high-risk patients, and post exposure
prophylaxis.
Prevention
acids. Environmental
control of surfaces should include inactivation of HAV by
formalin and/or
chlorine.
Passive Immunization: immune globulin.
Active Immunization: vaccination.
Source :
https://hepatitiseducation.med.ubc.ca/types-of-viral-hepatiti
s/
https://www.emedicinehealth.com/hepatitis_a/article_em.ht
m
https://www.webmd.com/g00/hepatitis/treatments-for-hepat
itis-a?i10c.ua=1&i10c.encReferrer=&i10c.dv=25
https://www.who.int/news-room/fact-sheets/detail/hepatitis-
a
Source:
https://www.webmd.com/hepatitis/digestive-diseases-hepati
tis-a#2
Wright, WF. Essentials of clinical infectious diseases.
Demos Medical Pub, 2013. 367 p.